Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer

NCT ID: NCT00430781

Last Updated: 2015-05-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 228 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2006-11-30
• Study Completion Date: 2011-07-31

Brief Summary

This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone or pazopanib alone in subjects with metastatic cervical cancer

Detailed Description

A Phase II, Open-Label, Randomized, Multicenter Trial of Pazopanib (GW786034) in Combination with Lapatinib (GW572016) Compared to Pazopanib Monotherapy and Lapatinib Monotherapy in Subjects with International Federation of Gynecology (FIGO) Stage IVB or Recurrent or Persistent Cervical Cancer with Zero or One Prior Chemotherapy Regimen for Advanced/Recurrent Disease

Conditions

Neoplasms, Uterine Cervix; Metastatic Cervical Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Combination arm

Pazopanib plus lapatinib

Group Type: EXPERIMENTAL

lapatinib (GW572016)

Intervention Type: DRUG

Lapatinib monotherapy

Lapatinib

Group Type: ACTIVE_COMPARATOR

lapatinib (GW572016)

Intervention Type: DRUG

Pazopanib monotherapy

Pazopanib

Group Type: ACTIVE_COMPARATOR

pazopanib (GW786034)

Intervention Type: DRUG

Interventions

pazopanib (GW786034)

Intervention Type: DRUG

lapatinib (GW572016)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• A subject will be eligible for inclusion in this study only if all of the following criteria are met:
• Signed, written informed consent prior to performing any study-related procedures
• Female subjects ≥18 years of age
• FIGO Stage IVB, or recurrent or persistent cervical cancer
• Life expectancy of at least 12 weeks
• ECOG status of 0 or 1.
• Histologically confirmed FIGO Stage IVB, or recurrent or persistent squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy
• Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest dimension to be recorded). Each lesion must be ≥ 20 mm when measured by conventional techniques, including palpitation, plain x-ray, CT and MRI, or ≥10 mm when measured by spiral CT.
• At least one "target lesion" to be used to assess response as defined by Response Evaluation Criteria in Solid Tumors (RECIST; Terasse, 2000). Tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy.
• Received 0 or 1 prior chemotherapy regimen for metastatic disease.
• Note: Chemotherapy given in combination with radiation therapy as a radiosensitizer does not count toward this prior therapy limit
• Recovered from the effects of surgery or chemotherapy. At least three weeks must have elapsed from the last administration of chemotherapy.
• Adequate organ and bone marrow function as defined in Table 1.
• Table 1:(Definitions for Adequate Organ Function)
• System:(Laboratory Values)
• Hematologic: Absolute neutrophil count (ANC)(≥ 1.5 X 109/L)Hemoglobin1(≥9 g/dL)Platelets(≥100 X 109/L)
• Hepatic: Total bilirubin (≤1.5 X ULN)AST and ALT (≤2.5 X ULN)
• Renal: Calculated creatinine clearance2 (≥50 mL/min)
• Urine protein3 (Negative, trace or +1 by dipstick urinalysis or <1.0 gram determined by 24 hour urine protein analysis.)
• Subjects may not have had a transfusion within 7 days of screening assessment.
• Calculated by Cockcroft Gault formula See Appendix 7: Renal Function Tests
• A patient should first be screened with dipstick urinalysis. If urine protein by dipstick analysis is ≥2+, then a 24-hour urine protein must be assessed and 24 hour urine protein must be <1 g protein to be eligible.
• Ability to swallow and retain oral medication.
• A female is eligible to enter and participate in this study if she is of:
• Non-childbearing potential (i.e., physiologically incapable of becoming pregnant), including any female who has had:
• A hysterectomy
• A bilateral oophorectomy (ovariectomy)
• A bilateral tubal ligation
• Is post-menopausal (total cessation of menses for ≥ 1 year)
• Childbearing potential, has a negative serum pregnancy test within 2 weeks prior to the first dose of study treatment, preferably as close to the first dose as possible, and agrees to use adequate contraception. GSK acceptable contraceptive methods, when used consistently and in accordance with both the product label and the instructions of the physician, are as follows:
• An intrauterine device with a documented failure rate of less than 1% per year.
• Vasectomized partner who is sterile prior to the female subject's entry and is the sole sexual partner for that female.
• Complete abstinence from sexual intercourse for 14 days before exposure to investigation product, through the dosing period, and for at least 21 days after the last dose of investigational product.
• Double-barrier contraception (condom with spermicidal jelly, foam suppository, or film; diaphragm with spermicide; or male condom and diaphragm with spermicide).

Note: Oral contraceptives are not reliable due to potential drug-drug interactions.

• Subjects must provide written informed consent prior to performance of study specific procedures or assessments, and must be willing to comply with treatment and follow-up as outlined in the protocol. Procedures conducted as apart of routine clinical management of the patient (e.g., blood count, imaging study) and obtained prior to signed informed consent may be utilized for screening purposes provided these tests are obtained as specified in the protocol

Exclusion Criteria

• A subject will not be eligible for inclusion in this study if any of the following criteria apply:
• Neuroendocrine or small cell carcinoma of the cervix.
• Prior use of any biologic therapy with VEGF, VEGFR, or ErbB1/ErbB2 inhibitors.
• Concurrent cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, and tumor embolization).
• Concurrent treatment with an investigational agent or participation in another clinical trial.
• Use of an investigational anti-cancer drug within 28 days or 5 half-lives, whichever is longer, preceding the first dose of study medication.
• Has taken or is taking prohibited medications listed in the protocol.
• Any serious and/or unstable pre-existing medical, psychiatric, or other conditions that could interfere with patient's safety, obtaining informed consent or compliance to the study.
• History of another malignancy. Note: Patients who have had another malignancy and have been disease-free for 5 years, or patients with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible.
• History or clinical evidence of central nervous system (CNS) metastases or leptomeningeal carcinomatosis. Routine screening with CNS imaging studies (computed tomography [CT] or magnetic resonance imaging [MRI]) is required only if clinically indicated.
• Malabsorption Syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel.
• Active peptic ulcer disease, inflammatory bowel disease, or other gastrointestinal condition increasing the risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 4 weeks prior to beginning therapy.
• Presence of uncontrolled infection.
• Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to pazopanib.
• Corrected QT interval (QTc) prolongation defined as QTc interval > 470 msecs.
• History of any one of the following cardiac conditions within the past 6 months:
• Cardiac angioplasty or stenting
• Myocardial infarction
• Unstable angina
• History of cerebrovascular accident or pulmonary embolus within the past 6 months.
• Has Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system (See Appendix 6)
• Poorly controlled hypertension (systolic blood pressure (SBP) of ≥ 140mmHg, or diastolic blood pressure (DBP) of ≥ 90mmHg).
• Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study entry. The blood pressure (BP) must be re-assessed on two occasions that are separated by a minimum of 24 hours. The mean SBP/DBP values from both BP assessments must be < 140/90mmHg in order for a subject to be eligible for the study.
• History of untreated deep venous thrombosis (DVT) within the past 6 months (e.g. calf vein thrombosis).
• Note: Patients with recent DVT who are treated with therapeutic anti-coagulant agents (excluding therapeutic warfarin) for at least 6 weeks are eligible.
• Presence of any non-healing, non-tumor related wound, fracture, or ulcer, or the presence of symptomatic peripheral vascular disease.
• Subjects with bilateral hydronephrosis which cannot be alleviated by ureteral stents or percutaneous drainage.
• Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks prior to beginning therapy, or anticipation of the need for a major surgical procedure during the course of the study; minor surgical procedures such as fine needle aspiration or core biopsy within 1 week prior to beginning therapy are also excluded.
• Unable to swallow and retain orally administered medication.
• Pregnant or lactating female.

• Minimum Eligible Age: 18 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

GSK Investigational Site

Los Angeles, California, United States

GSK Investigational Site

Orange, California, United States

GSK Investigational Site

Stanford, California, United States

GSK Investigational Site

Augusta, Georgia, United States

GSK Investigational Site

Boston, Massachusetts, United States

GSK Investigational Site

Albuquerque, New Mexico, United States

GSK Investigational Site

New York, New York, United States

GSK Investigational Site

Cleveland, Ohio, United States

GSK Investigational Site

Columbus, Ohio, United States

GSK Investigational Site

Oklahoma City, Oklahoma, United States

GSK Investigational Site

Chattanooga, Tennessee, United States

GSK Investigational Site

Dallas, Texas, United States

GSK Investigational Site

Capital Federal, Buenos Aires, Argentina

GSK Investigational Site

Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina

GSK Investigational Site

Neuquén, Neuquén Province, Argentina

GSK Investigational Site

Rosario, Santa Fe Province, Argentina

GSK Investigational Site

Santa Fe, Santa Fe Province, Argentina

GSK Investigational Site

San Miguel de Tucumán, Tucumán Province, Argentina

GSK Investigational Site

Quilmes, , Argentina

GSK Investigational Site

Brussels, , Belgium

GSK Investigational Site

Brussels, , Belgium

GSK Investigational Site

Ghent, , Belgium

GSK Investigational Site

Leuven, , Belgium

GSK Investigational Site

Roeselare, , Belgium

GSK Investigational Site

Calgary, Alberta, Canada

GSK Investigational Site

Vancouver, British Columbia, Canada

GSK Investigational Site

Hamilton, Ontario, Canada

GSK Investigational Site

Toronto, Ontario, Canada

GSK Investigational Site

Montreal, Quebec, Canada

GSK Investigational Site

Tallinn, , Estonia

GSK Investigational Site

Tartu, , Estonia

GSK Investigational Site

Bordeaux, , France

GSK Investigational Site

Caen, , France

GSK Investigational Site

Lille, , France

GSK Investigational Site

Marseille, , France

GSK Investigational Site

Strasbourg, , France

GSK Investigational Site

Villejuif, , France

GSK Investigational Site

Munich, Bavaria, Germany

GSK Investigational Site

Saarbrücken, Saarland, Germany

GSK Investigational Site

Halle, Saxony-Anhalt, Germany

GSK Investigational Site

Magdeburg, Saxony-Anhalt, Germany

GSK Investigational Site

Berlin, State of Berlin, Germany

GSK Investigational Site

Berlin, State of Berlin, Germany

GSK Investigational Site

Ahemdabad, , India

GSK Investigational Site

Mangalore, , India

GSK Investigational Site

New Delhi, , India

GSK Investigational Site

Trivandrum, , India

GSK Investigational Site

Cork, , Ireland

GSK Investigational Site

Dublin, , Ireland

GSK Investigational Site

Bari, Apulia, Italy

GSK Investigational Site

Napoli, Campania, Italy

GSK Investigational Site

Milan, Lombardy, Italy

GSK Investigational Site

Campobasso, Molise, Italy

GSK Investigational Site

Mexico City, , Mexico

GSK Investigational Site

Barcelona, , Spain

GSK Investigational Site

Barcelona, , Spain

GSK Investigational Site

La Laguna (Santa Cruz de Tenerife), , Spain

GSK Investigational Site

Madrid, , Spain

GSK Investigational Site

Marid, , Spain

GSK Investigational Site

Pamplona, , Spain

GSK Investigational Site

Bangkok, , Thailand

GSK Investigational Site

Chiang Mai, , Thailand

GSK Investigational Site

Khon Kaen, , Thailand

Countries

United States; Argentina; Belgium; Canada; Estonia; France; Germany; India; Ireland; Italy; Mexico; Spain; Thailand

References

Monk BJ, Mas Lopez L, Zarba JJ, Oaknin A, Tarpin C, Termrungruanglert W, Alber JA, Ding J, Stutts MW, Pandite LN. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2010 Aug 1;28(22):3562-9. doi: 10.1200/JCO.2009.26.9571. Epub 2010 Jul 6.

Reference Type: RESULT

PMID: 20606083 (View on PubMed)

Monk BJ, Pandite LN. Survival data from a phase II, open-label study of pazopanib or lapatinib monotherapy in patients with advanced and recurrent cervical cancer. J Clin Oncol. 2011 Dec 20;29(36):4845. doi: 10.1200/JCO.2011.38.8777. Epub 2011 Nov 14. No abstract available.

Reference Type: RESULT

PMID: 22084371 (View on PubMed)

de Jonge MJ, Hamberg P, Verweij J, Savage S, Suttle AB, Hodge J, Arumugham T, Pandite LN, Hurwitz HI. Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors. Invest New Drugs. 2013 Jun;31(3):751-9. doi: 10.1007/s10637-012-9885-8. Epub 2012 Oct 6.

Reference Type: DERIVED

PMID: 23054212 (View on PubMed)

Other Identifiers

VEG105281

Identifier Type: -

Identifier Source: org_study_id